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Background: This 52-week study evaluated the long-term safety and tolerability of capsaicin 8% w/w (179 mg) patch
repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy (PDPN).
Methods: Phase 3, multinational, open-label, randomised, controlled, 52-week safety study, conducted in Europe.
Patients were randomised to capsaicin 8% patch repeat treatment (30 or 60 min; 1–7 treatments with ≥ 8-week
intervals) to painful areas of the feet plus SOC, or SOC alone. The primary objective was the safety of capsaicin 8%
patch repeat treatment (30 min and 60 min applications) plus SOC versus SOC alone over 52 weeks, assessed by
changes in Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) total score from baseline to end of study (EOS).
Secondary safety endpoints included Utah Early Neuropathy Scale (UENS) assessments and standardised testing of
sensory perception and reflex function.
Results: Overall, 468 patients were randomised (30 min plus SOC, n = 156; 60 min plus SOC, n = 157; SOC alone, n =
155). By EoS, mean changes in Norfolk QOL-DN total score from baseline [estimated mean difference versus SOC alone;
90% CI for difference] were: 30 min plus SOC, −27.6% [−20.9; −31.7, −10.1]; 60 min plus SOC, −32.8% [−26.1; −36.8,
−15.4]; SOC alone, −6.7%. Mean changes [difference versus SOC alone] in UENS total score by EoS versus baseline
were: 30 min plus SOC, −2.1 [−0.9; −1.8, 0.1]; 60 min plus SOC, −3.0 [−1.7; −2.7, −0.8]; SOC alone, −1.2. No
detrimental deterioration was observed in any of the Norfolk or UENS subscales by EoS with capsaicin. Also, no
worsening in sensory perception testing of sharp, warm, cold and vibration stimuli was found with capsaicin by
EoS. Capsaicin treatment was well tolerated and the most frequent treatment-emergent adverse events were
application site pain (30 min, 28.2%; 60 min, 29.3%), burning sensation (30 min, 9.0%; 60 min, 9.6%) and
application site erythema (30 min, 7.7%; 60 min, 8.9%).
Conclusion: In patients with PDPN, capsaicin 8% patch repeat treatment plus SOC over 52 weeks was well
tolerated with no negative functional or neurological effects compared with SOC alone.
Trial Registration: ClinicalTrials.gov registration: NCT01478607. Date of registration November 21, 2011;
retrospectively registered.
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Peripheral neuropathic pain (PNP) is widely recognised
to have a significant impact on quality of life (QOL) [1].
Painful diabetic peripheral neuropathy (PDPN) has
been shown to affect many dimensions of patient QOL,
including mood, sleep, work, self-esteem and social re-
lationships, and has a particular impact on individuals
with suboptimally managed pain [2, 3]. Approximately
one in four people with type 2 diabetes will experience
some level of PDPN [4], which often presents as numb-
ness, tingling, burning, aching, electric shocks, or lanci-
nating pains [5].
Many patients with PDPN remain undiagnosed or
undertreated and few experience complete resolution of
pain. There is a clear unmet need for new therapeutic
options to improve current standard of care (SOC);
available treatments such as antidepressants, antiepilep-
tic drugs and opioids are often limited by contraindica-
tions and safety issues, and frequently have insufficient
efficacy to achieve adequate pain relief [6–8]. One al-
ternative to these treatments is the capsaicin 8% patch,
which contains 179 mg or 8% weight for weight capsa-
icin and is optimised for rapid delivery of a high con-
centration of capsaicin directly into the skin [9].
Defunctionalisation of hyperactive nociceptors in the
skin induced by the rapid delivery of capsaicin provides
fast, targeted, and sustained pain relief after a single
treatment. Furthermore, local application of the capsa-
icin 8% patch provides minimal systemic absorption,
without the potential for drug-drug interactions or re-
quirement for dose adjustment in elderly patients or
patients with renal or hepatic impairment [10].
The capsaicin 8% patch is well tolerated and provides
effective relief of pain for a variety of types of PNP
[11–16]. A single capsaicin 8% patch treatment has
demonstrated significant improvements in pain relief
versus a placebo patch over 12 weeks, and was well tol-
erated with no sensory deterioration in patients with
PDPN [16]. The present study in patients with PDPN
(PACE) was the first evaluation of the long-term safety
and tolerability of capsaicin 8% patch repeat treatment
plus SOC, compared with SOC alone, over 52 weeks.
The study had an open-label design; it primarily
assessed the safety of capsaicin 8% patch repeat treat-
ment, with efficacy of the capsaicin 8% patch in PDPN
assessed in the double-blind STEP study [16]. In this
study, the Norfolk Quality of Life-Diabetic Neuropathy
(QOL-DN) questionnaire was chosen as the primary
endpoint to assess the safety of capsaicin treatment.
The Norfolk scale is a validated patient-reported out-
come questionnaire, which captures the entire impact
of nerve fibre dysfunction on QOL in diabetic neur-
opathy [17]. The Norfolk tool includes the concentra-
tion of symptoms in the extremities and subtle loss offunction, such as fine motor impairments, slight sen-
sory changes, unique problems with proprioception
and balance and autonomic symptoms. The Norfolk
QOL-DN scale was therefore used to assess any func-
tional consequences associated with potentially dele-
terious effects of capsaicin treatment on peripheral
nerve endings in patients with PDPN.
Methods
Study design
PACE was a Phase 3, multinational, open-label, rando-
mised, controlled, 52-week safety study, conducted in
Europe between November 2011 and February 2014
(ClinicalTrials.gov Identifier: NCT01478607). The pri-
mary objective assessed the safety of repeat treatment
with the capsaicin 8% patch (QUTENZATM 179 mg
capsaicin patch, obtained from Astellas Pharma Europe
B.V., Leiden, The Netherlands) in patients with PDPN.
Following a screening visit, patients were assigned a
six-digit subject number allocated sequentially according
to site and randomised to capsaicin 8% patch (30 min)
plus SOC or capsaicin 8% patch (60 min) plus SOC or
SOC alone in a ratio of 1:1:1 by chronological order of
enrolment to receive treatment with the capsaicin 8%
patch to painful areas of the feet for either 30 min plus
SOC, 60 min plus SOC, or SOC alone. All patients were
pretreated with a eutectic mixture of local anaesthetics
(EMLA) containing lidocaine 2.5% and prilocaine 2.5%,
to limit pain or discomfort during the application period.
The 30-min application time was chosen to align with
the approved Summary of Product Characteristics [18].
A 60-min application time was also evaluated in order
to ensure that the safety objectives of the study were
fully covered with respect to possible exposure periods.
SOC was optimised for each patient at the discretion of
each investigator and was assessed at clinic visits and on
days 1 to 5 post-treatment, by completion of a rescue
pain medication diary. The treatment area was mapped
at screening and baseline visits, and re-mapped before
treatment if the treatment area changed. Treatment bor-
ders were defined by the most painful areas of the feet,
up to a total combined surface area of 1120 cm2 (four
patches) for both feet. Assessments were scheduled every
two months; clinic visits were scheduled for Month 2, 4, 6,
8, 10, and 12, and telephone contact was scheduled at
Month 1, 3, 5, 7, 9, and 11. Capsaicin 8% patch retreat-
ment could occur at both scheduled and unscheduled
clinic visits at the investigator’s discretion, but only after at
least 8 weeks had elapsed since the last treatment (Fig. 1).
Patients could not receive more than seven capsaicin 8%
patch treatments during the study. Although patients and
investigators were unblinded throughout the study, physi-
cians assessing neurological function were blinded to treat-
ment and not involved in the study in any other manner.
Fig. 1 Study design
*Capsaicin 8% patch treatment (Groups 1 and 2) took place at scheduled bi-monthly visits (P) or unscheduled visit at
intervals of at least 8 weeks. EoS visit for Groups 1 and 2 took place between 8 and 12 weeks after last patch application if patch was applied at
Visit 8 (Month 12) and between Week 52 and 56 for patients without a patch application at Visit 8 (Month 12). EoS visit for Group 3 took place
between Week 52 and 56. EoS end of study, SOC standard of care, UENS Utah Early Neuropathy Scale
Table 1 Key inclusion and exclusion criteria
Inclusion criteria
• Aged ≥ 18 years with a diagnosis
of PDPN confirmed by a score ≥ 3
on the MNSI
• HbA1c ≤ 9% (74.9 mmol/mol) at
3–6 months prior to screening
and at screening
• Stable glycaemic control for ≥ 6
months prior to screening visit
• Average daily pain score over
the last 24 h ≥ 4 (question 5 of
BPI-DN) at the screening and
the baseline visit
Exclusion criteria
• Primary pain associated with
PDPN in the ankles or above
• Significant pain (moderate or
above) due to an aetiology other
than PDPN
• Any amputation of lower extremity
• Clinically significant cardiovascular
disease within 6 months prior to
screening visit
• Any active signs of skin
inflammation around
onychomycosis sites such as
tenderness, redness, swelling
or drainage
• Body mass index ≥ 40 kg/m2
• Hypersensitivity to capsaicin
any capsaicin 8% patch excipients,
EMLA ingredients, or adhesives
• Use of oral or transdermal opioids
within 7 days preceding patch
application at baseline
• Pain that could not be clearly
differentiated from, or conditions
that might have interfered with,
the assessment of PDPN, e.g.,
claudication, fasciitis tendinitis
and arthritis
• Current or previous foot ulcer
• Severe renal disease as defined
by a creatinine clearance
< 30 mL/min
• Significant peripheral vascular
diseasea
• Impaired glucose tolerance
only – without diabetes mellitus
• Previous treatment with capsaicin
8% patch
• Use of any topical pain
medication on the painful areas
within 7 days preceding patch
application at baseline
BPI-DN Brief pain inventory-diabetic neuropathy version, EMLA eutectic mixture
of local anaesthetics, HbA1c glycosylated haemoglobin of A1c, MNSI Michigan
neuropathy screening instrument, PDPN painful diabetic peripheral neuropathy
aIntermittent claudication or lack of pulsation of either the dorsal pedis of
posterior tibias artery, or ankle-brachial systolic BP index of 0.80
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Patients were aged ≥18 years with a diagnosis of PDPN
due to type 1 or type 2 diabetes mellitus for ≥1 year
prior to the screening visit. Key criteria for inclusion and




The primary objective was to evaluate the safety of re-
peat treatment with the capsaicin 8% patch, assessed by
the percentage change from baseline to end of study
(EoS) in the Norfolk QOL-DN total score. The scale has
been shown to correlate with clinical Total Neuropathy
Score along with the different features of diabetic neur-
opathy such as small fibre function (including loss of
pain and thermal sensation), large fibre function (includ-
ing motor function and touch/pressure discrimination)
and autonomic nerve function [19]. The Norfolk QOL-
DN scale was specifically developed to reliably measure
changes in nerve function that translate into changes in
QOL, activities of daily living, and health of the individual,
where a reduction in score is associated with improved
function [17]. In this study, it was used to assess any func-
tional consequences of potential small nerve fibre dys-
function that may have been associated with capsaicin 8%
patch repeat treatment and adversely affected QOL.
Secondary endpoints
Secondary safety variables evaluated to support the pri-
mary endpoint included Norfolk QOL-DN subscale
scores, Utah Early Neuropathy Scale (UENS) [20] assess-
ments and standardised testing of sensory perception
and reflex function. Average pain score, pain severity
index, pain interference index, obtained from the Brief
Pain Inventory-Diabetic Neuropathy (question 5),response rates and Patient Global Impression of Change
were recorded as other secondary endpoints in this
study and will be reported separately.
Secondary Norfolk QOL-DN endpoints
Secondary safety variables related to Norfolk QOL-
DN included: percentage change from baseline in
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treatments; percentage change from baseline in Nor-
folk QOL-DN subscale scores (‘small fibre’, ‘symptoms’,
‘autonomic’, ‘physical functioning’, ‘activities of daily
living’); and absolute Norfolk QOL-DN total score. A
reduction in subscale score was associated with im-
proved function.
Utah early neuropathy scale
The UENS, a validated clinical tool developed to detect
and quantify signs of early neuropathy and identify mod-
est changes in the severity and spatial distribution of
sensation, was used to assess any functional conse-
quences of capsaicin treatment. A reduction in score in-
dicates improvement in sensory function over time.
Endpoints related to the UENS included: change from
baseline in UENS total score; change from baseline in
UENS total score by number of capsaicin treatments;
change from baseline in UENS subscale scores (‘pinprick
sensation’, ‘motor’, ‘allodynia/hyperaesthesia’, ‘large fibre’,
‘deep tendon reflex’); clinically significant change in
UENS total score (defined as a decrease of > 4 points
from baseline); and absolute UENS total score.
Sensory perception, reflex function and tolerability
Sensory examination was performed by neurologists as
well as by non-neurologist physician-investigators givenFig. 2 Category shift schema from baseline to EoS. EoS end of studystudy training, and were ideally performed by the same
person (Additional file 1). Physicians conducting sensory
examinations were blinded to treatment. ‘Bedside’ sen-
sory and reflex testing was performed on both feet at
baseline and EoS to identify any clinically relevant defi-
cits in sensory function. Ratings of evoked sensation
were compared with an asymptomatic site and recorded
using standardised categorical reporting scales: assess-
ment of warm, cold, and sharp sensations were rated as
‘absent’, ‘diminished’, ‘normal’, or ‘painful’. Sensation of vi-
bration on the dorsal surface of the great toe was rated
as ‘absent’, ‘markedly diminished’, ‘mild loss’, or ‘normal’
sensation. Testing areas on the dorsal surface included
the great toe, midpoint and medial malleolus and on the
plantar surface included the ball and midpoint. Achilles
tendon reflex assessment was rated as ‘absent’, ‘dimin-
ished’, ‘normal’, ‘hyperactive’, or ‘clonus’. To assess the
proportion of patients with changes in sensory perception
or reflex category, patients were judged to have improved,
stayed the same, or worsened depending on the change in
reported category at EoS versus baseline (Fig. 2).
A post-hoc analysis in patients who received the max-
imum of seven capsaicin 8% patch treatments was per-
formed to determine within-group changes of sensory
perception testing over time.
Adverse events (AEs) observed after randomisation
(post-randomisation AEs [PRAEs]) were collected for all
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patch arms with the SOC arm. Treatment-emergent AEs
(TEAEs) were observed following administration of the
capsaicin 8% patch, therefore no TEAEs are reported for
the SOC alone group. ‘Pain now’ Numeric Pain Rating
Scale (NPRS) scores, within 15 min and after 60 min fol-
lowing patch removal, were also assessed during the
study.
The change in use of concomitant medication was
assessed throughout the study; classes of interest were
antidepressants, antiepileptic drugs, and opioids.Statistical methods
Regarding sample size, the number of patients planned
for the trial were such that safety concerns related to the
Norfolk questionnaire would have been picked up. The
power calculation for this study used the principle of a
non-inferiority study with 90% power and a 95% one
sided confidence interval [CI]. The non-inferiority limit
was 20%. A clinically meaningful difference in the per-
centage reduction from baseline on the Norfolk scale
was chosen using data from a clinical trial in diabetic
peripheral neuropathy with ruboxistaurin [21], which
showed a drug effect of 37.2%, and selecting 20% as the
lower margin for clinically meaningful effect. A number
of statistical measures were used to describe the data:
descriptive statistics for absolute and change from base-
line values at each visit and at EoS; 90 or 95% CI for the
estimated mean difference between each of the active
treatment groups against SOC control for change from
baseline; percentage change from baseline at each post-
baseline analysis visit and EoS. As the objective of
the trial was to assess the safety and tolerability of
long-term capsaicin 8% patch treatment, no formal
statistical testing was performed to calculate p-valuesFig. 3 Patient flow. AE adverse event, SOC standard of carefor the difference between both capsaicin groups and
SOC alone. At EoS, for each subject, the last avail-
able observation was used with the last observation
carried forward (LOCF) imputation method. The re-
sults were also analysed using the baseline observa-
tion carried forward method.
The safety analysis set (SAS) included all patients who
received study treatment and was used for all analyses of
safety and analgesic effectiveness.Results
Patient disposition
Of the 555 patients screened, a total of 468 patients
were randomised at 71 centres across 11 European
countries (30 min plus SOC, n = 156; 60 min plus SOC,
n = 157; SOC alone, n = 155). A total of 388 patients
completed the study (30 min plus SOC, n = 132; 60 min
plus SOC, n = 128; SOC alone, n = 128); 80 patients
(17.1%) discontinued the study post baseline, most
commonly due to withdrawal of consent (n = 44) and
adverse events (n = 18; Fig. 3).
Baseline characteristics were similar across treatment
groups and specifically, were comparable for age, glyco-
sylated haemoglobin of A1c (HbA1c), average daily pain,
Norfolk QOL-DN total score, UENS total score, dur-
ation of PDPN and use of prior treatments for PDPN
(including pain medications and SOC) (Table 2).
The most commonly prescribed categories of pain
medications during the study were analgesics and anti-
epileptics; the most commonly prescribed drugs for pain
during the study were gabapentin and pregabalin
(Table 3).
The average interval between each capsaicin retreat-
ment was 68.4 days in the capsaicin 30-min group and
68.3 days in the 60-min group. The mean number of
Table 2 Summary of demographics and baseline characteristics (safety analysis set)
Parameter Capsaicin 8% patch
(30 min) + SOC
(n = 156)
Capsaicin 8% patch





Male 74 (47.4) 79 (50.3) 71 (45.8)
Female 82 (52.6) 78 (49.7) 84 (54.2)
Ethnicity, n (%)
Caucasian 154 (98.7) 155 (98.7) 154 (99.4)
Other 2 (1.3) 2 (1.3) 1 (0.6)
Age, years
Mean [SD] 60.9 [10.9] 61.0 [10.3] 59.1 [10.3]
Weight, kg
Mean [SD] 86.6 [14.5] 86.7 [16.4] 89.6 [17.6]
Height, cm
Mean [SD] 169.7 [8.9] 169.7 [9.0] 169.3 [10.9]
Body mass index, kg/m2
Mean [SD] 30.1 [4.6] 30.1 [5.0] 31.2 [5.0]
Duration of PDPN, years
Mean [SD] 4.1 [3.7] 4.4 [3.9] 4.4 [3.6]
Pain medications before baseline, n (%)
Overall 70 (44.9) 71 (45.2) 79 (51.0)
Analgesicsa 56 (35.9) 54 (34.4) 59 (38.1)
Antiepileptics 44 (28.2) 49 (31.2) 52 (33.5)
Psycholeptics 22 (14.1) 19 (12.1) 24 (15.5)
Anti-inflammatory/antirheumatic products 14 (9.0) 12 (7.6) 17 (11.0)
Topical joint/muscular pain productsb 14 (9.0) 11 (7.0) 15 (9.7)
Baseline average pain score (BPI-DN question 5)
Mean [SD] 5.6 [1.3] 5.6 [1.4] 5.5 [1.3]
Baseline Norfolk QOL-DN score
Mean [SD] 42.8 [19.5] 40.6 [18.3] 41.0 [18.5]
Baseline UENS total score
Mean [SD] 17.0 [7.4] 16.5 [7.0] 15.6 [6.2]
HbA1c at screening
Mean, % [SD] 7.3 [1.0] 7.4 [1.0] 7.4 [1.0]
Mean, mmol/mol [SD] 56.6 [10.8] 57.5 [10.8] 57.6 [11.4]
BPI-DN Brief pain inventory diabetic neuropathy, HbA1c glycosylated haemoglobin of A1c, PDPN painful diabetic peripheral neuropathy, QOL-DN Quality-of-life
questionnaire for diabetic neuropathy, SD standard deviation, SOC standard of care
aAnalgesics were categorised by analgesics, anilides, natural opium alkaloids, other analgesics and antipyretics, other opioids, pyrazolones and salicylic acid
and derivatives
bAnti-inflammatory preparations, non-steroidals for topical use, preparations with salicylic acid derivatives
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(30 min, 1.53; 60 min, 1.42) and the mean duration of
patch application was 30.2 min in the 30-min group and
60.2 min in the 60-min group. Over half of patients in the
capsaicin 8% patch groups received the maximum seven
capsaicin treatments (167/313 [53.4%]) (Additional file 2:
Figure S1 and Additional file 3: Figure S2).Safety
Norfolk QOL-DN
No deterioration (denoted by a reduction in score) in
mean (estimated mean difference versus SOC alone; 90%
CI for difference) Norfolk QOL-DN total score from
baseline to EoS was observed in the capsaicin 8% patch
plus SOC groups (30 min, −27.6% [−20.9; −31.7, −10.1];
Table 3 Pain medication during the study (safety analysis set)
Pain medicationa Capsaicin 8% patch
(30 min) + SOC (n = 156)
Capsaicin 8% patch
(60 min) + SOC (n = 157)
SOC (n = 155)
Overall, n (%) 98 (62.8) 105 (66.9) 107 (69.0)
Most commonly used category (>10 % patients in either group), n (%)
Analgesicsb 79 (50.6) 84 (53.5) 81 (52.3)
Antiepileptics 54 (34.6) 57 (36.3) 73 (47.1)
Topical products for joint and muscular pain 30 (19.2) 35 (22.3) 29 (18.1)
Anti-inflammatory/antirheumatic products 29 (18.6) 35 (22.3) 30 (19.4)
Psycholeptics 24 (15.4) 22 (14.0) 40 (25.8)
Stomatological preparations 18 (11.5) 22 (14.0) 18 (11.6)
Psychoanaleptics 16 (10.3) 6 (3.8) 21 (13.5)
Ophthalmologicalsc 15 (9.6) 20 (12.7) 16 (10.3)
Most commonly used drugs (>5% patients in any group), n (%)
Gabapentin 26 (16.7) 26 (16.6) 35 (22.6)
Pregabalin 24 (15.4) 22 (14.0) 39 (25.2)
Paracetamol 23 (14.7) 36 (22.9) 6 (3.9)
Tramadol 16 (10.3) 14 (8.9) 6 (3.9)
Diclofenac 12 (7.7) 13 (8.3) 12 (7.7)
Ibuprofen 11 (7.1) 15 (9.6) 14 (9.0)
Metamizole 10 (6.4) 10 (6.4) 5 (3.2)
Duloxetine 9 (5.8) 3 (1.9) 10 (6.5)
Carbamazepine 7 (4.5) 14 (8.9) 10 (6.5)
Alpha lipoic acid 3 (1.9) 1 (0.6) 8 (5.2)
SOC standard of care
aMedication used for pain (check box of ‘pain medication’ is YES on electronic case report form [eCRF])
bAnalgesics were categorised by class: anilides, natural opium alkaloids, other analgesics and antipyretics, other opioids, pyrazolones, and salicylic acid and derivatives
cOphthalmologicals (eye treatments) were categorised by anti-inflammatory agents and nonsteroids, local anaesthetics, corticosteroids (plain) and
other ophthalmologicals
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SOC alone (−6.7%) (Fig. 4). By EoS, patients who re-
ceived the maximum seven capsaicin treatments plus
SOC also had no deterioration in Norfolk QOL-DN
when compared with the overall SAS population (Fig. 4).
The mean difference [90% CI] from baseline in Nor-
folk QOL-DN total score between groups increased
throughout the study (Fig. 5).
In addition, no deterioration in any of the Norfolk
QOL-DN subscale scores from baseline to EoS was ob-
served in both capsaicin plus SOC groups versus SOC
alone (Fig. 4).
Utah early neuropathy scale
The mean change [SD] from baseline to EoS in absolute
UENS total score was −2.1 [5.0] with capsaicin 30 min
and −3.0 [5.1] with capsaicin 60 min, compared with
−1.2 [4.2] in SOC alone group (least squares mean dif-
ference [90% CI]: 30 min, −0.9 [−1.8, 0.1]; 60 min: −1.7
[−2.7, −0.8]) (Fig. 6).
No deterioration in UENS total score was noted in pa-
tients who received the maximum seven capsaicintreatments plus SOC compared with the overall SAS
population (Fig. 6). A clinically significant improvement
in UENS total score (defined as a decrease of > 4 points
from baseline) was observed in 35.6 and 37.9% of pa-
tients in the capsaicin 30-min and capsaicin 60-min
groups, respectively, compared with 22.5% of patients in
the SOC alone group.
Regarding UENS subscales, no deterioration in mean [SD]
‘pinprick sensation’ score was observed in the capsaicin plus
SOC groups compared with SOC alone (30 min, −1.4 [3.84];
60 min, −2.2 [3.99]; SOC, −0.7 [3.14]). There were no notice-
able differences or only minimal changes across treatment
groups in the otherUENSsubscale scores (Fig. 6).
No differences were observed between treatment
groups (data not show) using the baseline observation
carried forward method.
Sensory perception and reflex testing
The capsaicin 8% patch had no negative impact on sen-
sory perception and reflex testing and the majority of
patients had no change from baseline to EoS (Fig. 7,
Additional file 4: Table S1). In patients who received the
Fig. 4 Mean percentage change from baseline to end of study in Norfolk QOL-DN scores (LOCF) (SAS)
Treatment group comparisons are least squares mean difference [90% CI]. CI confidence interval, LOCF last observation carried forward, SAS safety
analysis set, SOC standard of care
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negative impact from baseline to EoS (Additional file 5:
Figure S3). A shift to worsened sensation was reported
by a lower proportion of patients in both the overall
population and the capsaicin 8% patch seven treatment
cohort (Fig. 7, Additional file 5: Figure S3).Fig. 5 Mean percentage change in Norfolk QOL-DN total score from baseline
In patients who received a capsaicin treatment at Month 12 and had an end
Month 14 was: 30 min, −36.1% [51.6] (n = 79); 60 min, −40.2% [39.4] (n = 76). SBy EoS, the proportion of patients reporting ‘normal’
sensation increased for the majority of tests in all three
groups; however, reporting of ‘normal’ sharp (on ball of
foot), warm, and cold sensation was greater for capsa-
icin groups plus SOC versus SOC alone (Fig. 8a). The
proportion of patients reporting ‘absent’ sharp (onduring the study (SAS)
of study visit at Month 14, mean [SD] change in Norfolk total score by
AS safety analysis set, SOC standard of care
Fig. 6 Mean change in UENS total and subscale scores from baseline to EoS (LOCF) (SAS)
Treatment group comparisons are least squares mean difference [90% CI]. CI confidence interval, EoS end of study, LOCF last observation carried
forward, SAS safety analysis set, SOC standard of care
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decreased in all groups by EoS, with the greatest change
in warm, cold and vibration seen in the capsaicin
60 min plus SOC group (Fig. 8b). There was also a de-
crease in the proportion of patients, in all groups,
reporting ‘absent’ or ‘markedly diminished’ vibrationFig. 7 Proportion of patients reporting improved, unchanged, or worsened
C30 + SOC, capsaicin 8% patch (30 min) + SOC (n = 150); C60 + SOC, capsai
EoS end of study, SAS safety analysis set, SOC standard of care (n = 143); n isensation by EoS, and this was accompanied by a corre-
sponding increase in ‘mild loss’ vibration in all groups
(Fig. 8b). These findings were mirrored in the subset of
patients who received the maximum seven capsaicin
treatments plus SOC, with more patients in the capsa-
icin groups reporting ‘normal’ sensation for sharp,sensory or reflex function by EoS (SAS)
cin 8% patch (60 min) + SOC (n = 146)
s number of patients with non-missing data
Fig. 8 a and b Change in proportion of patients reporting sensory and reflex testing from baseline to EoS (SAS)
C30 + SOC, capsaicin 8% patch (30 min) + SOC (n = 156); C60 + SOC, capsaicin 8% patch (60 min) + SOC (n = 157)
EoS end of study, SAS safety analysis set, SOC standard of care (n = 155)
Vinik et al. BMC Neurology  (2016) 16:251 Page 10 of 14warm, and cold tests compared with the SOC alone
group (Additional file 6: Figure S4, Additional file 7:
Table S2). Also in the seven treatments subset, the
proportion of patients reporting ‘absent’ sharp (on
plantar midpoint), warm, cold and vibration sensation
decreased in all groups by EoS, with the greatest
change in warm and cold seen in the capsaicin 60 min
plus SOC group (Additional file 8: Figure S5). In
addition, fewer patients in the seven treatment subset
reported ‘absent’ vibration sensation by EoS,accompanied by a corresponding increase in ‘mild loss’
vibration (Additional file 8: Figure S5).
Tolerability
Mean ‘pain now’ NPRS scores after patch application
were low (≤3.5); peak mean pain scores were observed
within 15 min after the first patch removal (3.5; median
3.0, interquartile range 2.0–5.0) to 60 min after the first
patch removal (3.3; median 3.0, interquartile range 1.0–
5.0). However, ‘pain now’ NPRS scores decreased after
Vinik et al. BMC Neurology  (2016) 16:251 Page 11 of 14the second patch removal and were stable from the fifth
to the last patch removal. More patients in the capsaicin
8% patch 60-min group used concomitant analgesics for
application site-related pain (29.9%) compared with the
30-min group (22.4%).
The proportion of patients reporting any PRAE was
67.3% (30 min plus SOC), 69.4% (60 min plus SOC) and
48.4% (SOC alone) (Table 4), and the majority of PRAEs
were of mild or moderate severity.
Severe PRAEs were reported by 12.2, 7.6 and 6.5% in
the patients in the capsaicin 30 min, capsaicin 60 min,
and SOC alone, groups, respectively; overall, these severe
PRAEs were most commonly categorised as cardiac dis-
orders, infections and infestations, and musculoskeletal
and connective tissue disorders. The difference in PRAEs
between the capsaicin plus SOC groups and SOC alone
was primarily due to the reporting of application site
pain or erythema in the capsaicin groups, which were
predominately mild or moderate in severity (Table 4).
TEAEs were similar in the capsaicin 8% patch 30-min
and 60-min plus SOC treatment groups (66.7 and 67.5%,
respectively) and were generally mild or moderate in se-
verity (Table 4). Over one-third of TEAEs in the capsa-
icin groups were application site reactions; the type and
frequency of these reactions were comparable between
both capsaicin groups. The proportion of patients with
application site reactions decreased throughout the
study, from between the first and second to between the
sixth and seventh treatments (application site pain:
30 min, −6.9%; 60 min, −7.9%, burning sensation:
30 min, −2.8%; 60 min −2.2%). Four patients in the 60-
min group discontinued due to drug-related TEAEs
(four events: muscle spasms, rectal adenocarcinoma,
neuralgia, and psoriasis); no drug-related discontinua-
tions were reported in the 30-min group. Severe TEAEs
were reported by 12.2% in the 30-min group and 7.6%
in the 60-min group; severe TEAEs considered as drug
related were reported by 2.6% in the 30-min group and
1.9% in the 60-min group. Serious TEAEs considered as
drug related were reported by two patients in the 60-min
group (three events: angina pectoris, rectal adenocarcin-
oma and accelerated hypertension), and by no patients in
the 30-min group. These events were officially classified
as drug-related by the investigator because causation
could not be excluded; however, the sponsor considered it
unlikely that repeat treatment with capsaicin 8% patch
was the cause of these events. Four deaths were reported
during the study: capsaicin 30 min, multiple injuries and
brain death (n = 1); capsaicin 60 min, hypotension (n = 1);
SOC alone, pneumonia (n = 1), atrial fibrillation (n = 1).
None of the deaths were considered to be drug related by
the investigator. The only finding of note from vital sign
and laboratory analyses was that the change in HbA1c
from screening to EoS was marginally greater in the SOCalone arm (0.24%), compared with the capsaicin 30 min
(0.06%) and 60 min (0.06%) arms, although HbA1c levels
were generally controlled throughout the study.
Concomitant medications
Overall, there was no decrease in the use of concomitant
medications in any of the treatment groups throughout
the study; use of concomitant medications was compar-
able from baseline to EoS in both capsaicin groups
(Additional file 9: Table S3). The proportion of patients
using antiepileptics at the end of the study was compar-
able with the proportion reported at baseline for both
capsaicin groups. However, the proportion of patients
using antiepileptic drugs had increased by > 10% in the
SOC alone group at the end of the study. Small increases
were also observed in antidepressant and opioid use in
the SOC alone group from baseline to the EoS.
Discussion
In patients with PDPN, capsaicin 8% patch repeat treat-
ment plus SOC over 52 weeks was well tolerated, had
no negative functional or neurological effects and raised
no new safety concerns compared with SOC therapy.
While the efficacy and safety of a single capsaicin 8%
treatment has been previously characterised in patients
with PDPN in the double-blind STEP study [16], the
open-label PACE study was the first to assess the long-
term safety and tolerability of repeated treatment over
52 weeks in PDPN. Capsaicin 8% patch repeat treatment
plus SOC was not associated with any deterioration in
Norfolk QOL-DN total or subscale scores compared
with SOC alone. For the safety endpoints, few differ-
ences were observed in results between the 30-min and
60-min capsaicin groups.
Regarding the UENS total score and ‘pinprick sensation’
subscale, and sharp, cold, warm and vibration sensation
on standardised neurological tests, no deterioration was
observed with capsaicin 8% patch repeat treatment. By
EoS, the majority of patients showed no change in sensa-
tion category, indicating that the changes observed in
Figs. 8a and b and Additional file 6: Figure S4 and
Additional file 8: Figure S5 were predominantly in pa-
tients who transitioned from ‘absent’ to ‘diminished’
or to ‘normal’ during the study. Taken together, these
findings indicate that there was no small fibre medi-
ated sensory loss with capsaicin 8% patch repeat treat-
ment. The sensory testing observations in the subset of
patients who received seven consecutive capsaicin treat-
ments demonstrated that regular, repeat treatment with
the capsaicin 8% patch was also not associated with deteri-
oration in sensory function.
Alongside the double-blind STEP study, the PACE study
formed part of a successful regulatory submission to re-
move the restriction of treatment with capsaicin 8% patch
Table 4 Summary of PRAEs, TEAEs, and drug-related TEAEs
(safety analysis set)
Event, n (%) Capsaicin 8%
patch








PRAEs 105 (67.3) 109 (69.4) 75 (48.4)
Mild PRAEs 83 (53.2) 89 (56.7) 55 (35.5)
Moderate PRAEs 50 (32.1) 54 (34.4) 34 (21.9)





54 (34.6) 53 (33.8) 10 (6.5)
Application site pain 44 (28.2) 46 (29.3) 0 (0)
Mild 23 (14.7) 28 (17.8) 0 (0)
Moderate 19 (12.2) 16 (10.2) 0 (0)
Severe 2 (1.3) 2 (1.3) 0 (0)
Application site
erythema
12 (7.7) 14 (8.9) 0 (0)
Mild 12 (7.7) 13 (8.3) 0 (0)
Moderate 0 (0) 1 (0.6) 0 (0)




7 (4.5) 8 (5.1) 3 (1.9)
TEAEs 104 (66.7) 106 (67.5) N/A
Application site
reactions
60 (38.5) 69 (43.9)
TEAEs most
commonly reported
(>5% of each group)
N/A
Application site pain 44 (28.2) 46 (29.3)
Burning sensation 14 (9.0) 15 (9.6)
Application site
erythema
12 (7.7) 14 (8.9)




7 (4.5) 8 (5.1) N/A




0 (0) 4 (2.5) N/A
Muscle spasmsb 0 (0) 1 (0.6)
Rectal
adenocarcinomac
0 (0) 1 (0.6)
Neuralgiad 0 (0) 1 (0.6)
Plantar psoriasise 0 (0) 1 (0.6)
Severe TEAEs 19 (12.2) 12 (7.6) N/A
Drug-relateda
severe TEAEs
4 (2.6) 3 (1.9) N/A
Table 4 Summary of PRAEs, TEAEs, and drug-related TEAEs
(safety analysis set) (Continued)
Application site pain 2 (1.3) 2 (1.3)
Rectal
adenocarcinomac
0 (0) 1 (0.6)
Burning sensation 1 (0.6) 0 (0)
Hypoaesthesia 1 (0.6) 0 (0)
Serious TEAEs 20 (12.8) 13 (8.3) N/A
Drug-relateda serious
TEAEs
0 (0) 2 (1.3) N/A
Angina pectorisf 0 (0) 1 (0.6)
Accelerated
hypertensiong
0 (0) 1 (0.6)
Rectal
adenocarcinomac
0 (0) 1 (0.6)
Deaths 1 (0.6) 1 (0.6) 2 (1.3)
N/A not applicable in SOC alone group, PRAE post-randomisation adverse
event, SOC standard of care, TEAE treatment-emergent adverse event
aPossible or probable, as assessed by the investigator, or records where
relationship is missing
bMuscle spasms in both legs of one patient were considered unlikely to have
been caused by the capsaicin 8% patch, but a causal association could not be
excluded. The same patient also previously reported cramps in the toes
cRectal adenocarcinoma was considered unlikely to have started during the
study and reach grade T3 within 129 days; however, a causal association with
the capsaicin 8% patch could not be excluded
dOne case of neuralgia was considered probably related to the study drug in
view of the close temporal association with dosing and the known ability of
the capsaicin 8% patch to cause application site pain
eAlthough the capsaicin 8% patch could not be excluded as a cause of one
event of plantar psoriasis, the mechanism by which it could cause an
autoimmune condition such as psoriasis is unclear and a causal association
was considered unlikely
f, gAngina pectoris and accelerated hypertension were likely related to the
patient’s co-existing ischemic heart disease and hypertension but a causal
association with the capsaicin 8% patch could not be excluded
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patch is now indicated for the treatment of peripheral
neuropathic pain in adults either alone or in combination
with other medicinal products for pain in Europe [18].
Although the open-label design of this study may be
perceived as more representative of capsaicin 8% patch
repeat treatment in clinical practice than in a double-
blind design, the observed safety evaluations may have
been biased by the open-label design. Although the phy-
sicians assessing neurological function were blinded to
treatment, patients and investigators were unblinded,
which may have impacted on the findings. As the pri-
mary objective of this open-label study was to assess the
safety and tolerability of capsaicin 8% patch repeat treat-
ment, p-values were not calculated to supplement the
90% CIs for the between-group differences each month.
Furthermore, differences between treatment groups in
an open-label study may be caused by the fact that pa-
tients know which treatment they are receiving. The
LOCF imputation method is a conservative method to
estimate the treatment effect. The underlying assump-
tion is that subjects that withdraw have worse efficacy
Vinik et al. BMC Neurology  (2016) 16:251 Page 13 of 14than those that stay in the trial. The LOCF imputation
method did use the data of withdrawn subjects and
therefore, theoretically, gave worse results in this study
than from a non-imputed analysis. As the limitations of
the LOCF for missing data methodology are recognised,
the results were also analysed using the baseline obser-
vation carried forward method, and no differences in the
results were observed. Quantitative Sensory Testing
(QST) was not performed in this multicenter study and
instead, ‘bedside’ sensory testing was used. Although it
was not feasible in this multicenter study to provide ad-
equate QST training across all centres, or standardise all
assessments in all study centres, potential advantages of
QST such as quantification of sensory deficits and allo-
dynia/hyperalgesia, and standardisations of values for
several painful sites [22, 23] may have provided greater
sensitivity in detecting small variations of thermal or
mechanical deficits, and reduced possible variability in
testing within and between centres. Other limitations
include the impact of concomitant opioid use on the
results and that the patient population was 99% Cauca-
sian, and therefore the findings may not be widely ap-
plicable to patients of other ethnicity.Conclusion
Repeat treatment with the capsaicin 8% patch plus SOC
versus SOC alone over 52 weeks in patients with PDPN
was well tolerated and consistent with the established
safety profile of the capsaicin 8% patch. Capsaicin plus
SOC had no negative functional or neurologic effects
compared with SOC alone.Additional files
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